Stock futures are slightly lower this morning as investors absorb a tech-led pullback and await pivotal catalysts, including Federal Reserve minutes and the highly anticipated Jackson Hole symposium. Overall, equity markets are navigating heightened sensitivity to valuation concerns and earnings surprises.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Broader sentiment is tempered by a tale of two expectations. Markets are optimistic about the likelihood of a September rate cut, yet equally anxious about elevated valuations and geopolitical volatility. Analysts warn that with discounts rare across sectors, even moderate setbacks, could trigger a 5% to 10% correction.
In pre-market trading, S&P 500 futures are down 0.08%, Nasdaq futures fell 0.20% and Dow futures are up 0.02%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly, and subscribe to the Fly By on YouTube.
HIGHER –
- Rocket Pharmaceuticals (RCKT) up 24% after announcing that the FDA has lifted the clinical hold on the company’s pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease
- Hertz (HTZ) up 10% after reporting Hertz Car Sales has joined Amazon (AMZN) Autos allowing shoppers to browse, finance, and purchase from a selection of thousands of pre-owned vehicles
- Dayforce (DAY) up 3% after confirming it is engaging in advanced discussions with Thoma Bravo regarding a potential acquisition
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- FDA Lifts Hold on Rocket’s Danon Disease Trial
- Rocket Pharmaceuticals announces clinical hold lifted on RP-A501 trial
- Rocket Pharmaceuticals: Hold Rating Amid Clinical and Financial Uncertainties
- Rocket Pharma Reports Q2 2025 Financial Results
- Rocket Pharmaceuticals: Strategic Focus on AAV Gene Therapy and Financial Resilience Justifies Buy Rating